1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study 2 RESEARCH METHODOLOGY 3 EXECUTIVE SUMMARY 4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Increased Awareness About the Potential Benefits of Targeted Alpha Therapy 4.2.2 Increasing Number of Patients with Cardiac and Cancer Ailments 4.3 Market Restraints 4.3.1 Short Half-life of Radiopharmaceuticals 4.3.2 Stringent Regulatory Framework and Reimbursement Issues 4.3.3 Need for High Capital Investment 4.4 Porter's Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry 5 MARKET SEGMENTATION 5.1 Type of Radionuclide 5.1.1 Terbium (Tb-149) 5.1.2 Astatine (At-211) 5.1.3 Bismuth (Bi-212) 5.1.4 Actinium (Ac-225) 5.1.5 Radium (Ra-223) 5.1.6 Lead (Pb-212) 5.1.7 Bismuth (Bi -213) 5.2 Medical Application 5.2.1 Glioma 5.2.2 Melanoma 5.2.3 Pancreatic Cancer 5.2.4 Ovarian Cancer 5.2.5 Thyroid 5.2.6 Bone Metastasis 5.2.7 Lymphoma 5.2.8 Endocrine Tumors 5.2.9 Other Medical Applications 5.3 Geography 5.3.1 North America 5.3.1.1 United States 5.3.1.2 Canada 5.3.1.3 Mexico 5.3.2 Europe 5.3.2.1 Germany 5.3.2.2 United Kingdom 5.3.2.3 France 5.3.2.4 Italy 5.3.2.5 Spain 5.3.2.6 Rest of Europe 5.3.3 Asia-Pacific 5.3.3.1 China 5.3.3.2 Japan 5.3.3.3 India 5.3.3.4 Australia 5.3.3.5 South Korea 5.3.3.6 Rest of Asia-Pacific 5.3.4 Middle East & Africa 5.3.4.1 GCC 5.3.4.2 South Africa 5.3.4.3 Rest of Middle East & Africa 5.3.5 South America 5.3.5.1 Brazil 5.3.5.2 Argentina 5.3.5.3 Rest of South America 6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Actinium Pharmaceutical Inc. 6.1.2 Alpha Tau Medical Ltd 6.1.3 Bayer AG 6.1.4 Fusion Pharmaceuticals 6.1.5 IBA Radiopharma Solutions 6.1.6 RadioMedix Inc. 6.1.7 Telix Pharmaceuticals Ltd 7 MARKET OPPORTUNITIES AND FUTURE TRENDS

- Actinium Pharmaceutical Inc. - Alpha Tau Medical Ltd - Bayer AG - Fusion Pharmaceuticals - IBA Radiopharma Solutions - RadioMedix Inc. - Telix Pharmaceuticals Ltd